{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.2","upperLimit":"66.2","value":"58.3"},{"groupId":"OG001","lowerLimit":"12.5","upperLimit":"31.8","value":"21.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response \\[ PR\\]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG000","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG001","title":"High-Risk Group"}],"paramType":"NUMBER","populationDescription":"Eligible intermediate and high risk group patients who received at least 1 dose of methotrexate were included in this analysis. One of the high risk patients did not start therapy and was excluded.","reportingStatus":"POSTED","timeFrame":"From on-study date to 2 months after completion of induction chemotherapy (up to 4 months after on-study date)","title":"Percentage of Patients With Objective Responses Rate to Induction Chemotherapy","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}